Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 12/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL698604 | 0.79 | CES2 (0.41) | CES2CES1RIPK1CA2P2RX7 | |
| SCHEMBL6864273 | 0.78 | CES2 (0.46) | CES2CES1RIPK1CA2P2RX7 | |
| SCHEMBL2957481 | 0.77 | CES2 (0.43) | CES2CES1RIPK1P2RX7 | |
| SCHEMBL892933 | 0.77 | CES2 (0.45) | CES2CES1RIPK1CA2P2RX7 | |
| SCHEMBL489658 | 0.76 | CES2 (0.37) | CES2CES1RIPK1CA2P2RX7 | |
| SCHEMBL17552654 | 0.76 | CES2 (0.37) | CES2CES1RIPK1CA2P2RX7 | |
| SCHEMBL15903837 | 0.75 | CES2 (0.38) | CES2CES1RIPK1CA2P2RX7 | |
| SCHEMBL1241765 | 0.75 | CES2 (0.38) | CES2CES1RIPK1CA2P2RX7 | |
| SCHEMBL2151373 | 0.75 | CES2 (0.43) | CES2CES1RIPK1CA2P2RX7 | |
| SCHEMBL2870153 | 0.75 | RIPK1 (0.45) | CES2CES1RIPK1CA2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763562-B2 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
| US-7214746-B2 | Phosphorus bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-20050239981-A1 | Phosphorus bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239981-A1 | Phosphorus bridged metallocene compounds for olefin polymerization | PYM1, ZNF207, POLL | CES2 4308/4885CES1 4742/4885RIPK1 224/4885 |
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | AP2M1, AP1M1, PYM1 | CES2 4242/4885CES1 4655/4885RIPK1 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.